Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Selena Quintanilla documentary 'Selena y Los Dinos: A Family's Legacy' is coming to Netflix- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- How will the universe end?
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Opening Achievement: 8 Methodologies for Compelling Using time productively
- 2023's Best 10 Cell phone Advancements You Can't Miss
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- Kids with smartphones by age 12 are at higher risk of health issues, study finds
